Zobrazeno 1 - 10
of 213
pro vyhledávání: '"Marco L. Davila"'
Autor:
Hiroshi Kotani, Tomoyoshi Yamano, Justin C. Boucher, Shigeki Sato, Hiroyuki Sakaguchi, Koji Fukuda, Akihiro Nishiyama, Kaname Yamashita, Koushiro Ohtsubo, Shinji Takeuchi, Takumi Nishiuchi, Hiroko Oshima, Masanobu Oshima, Marco L. Davila, Seiji Yano
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-6 (2024)
Abstract Precision medicine has drastically changed cancer treatment strategies including KRAS-mutant cancers which have been undruggable for decades. While intrinsic or acquired treatment resistance remains unresolved in many cases, epigenome-target
Externí odkaz:
https://doaj.org/article/b9b2e0380ce9438081e69ef411f40371
Autor:
Hiroshi Kotani, Hiroko Oshima, Justin C. Boucher, Tomoyoshi Yamano, Hiroyuki Sakaguchi, Shigeki Sato, Koji Fukuda, Akihiro Nishiyama, Kaname Yamashita, Koushiro Ohtsubo, Shinji Takeuchi, Takumi Nishiuchi, Masanobu Oshima, Marco L. Davila, Seiji Yano
Publikováno v:
Journal of Biomedical Science, Vol 31, Iss 1, Pp 1-13 (2024)
Abstract Background KRAS mutations frequently occur in cancers, particularly pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Although KRAS G12C inhibitors have recently been approved, effective precision therapies
Externí odkaz:
https://doaj.org/article/e76a3f8454924a68ab32ec86f27f0f26
Autor:
Justin C. Boucher, Bishwas Shrestha, Paresh Vishwasrao, Mark Leick, Estelle V. Cervantes, Tayyebb Ghafoor, Kayla Reid, Kristen Spitler, Bin Yu, Brian C. Betts, Jose A. Guevara-Patino, Marcela V. Maus, Marco L. Davila
Publikováno v:
Molecular Therapy: Oncolytics, Vol 31, Iss , Pp 100751- (2023)
CD33 and CD123 are expressed on the surface of human acute myeloid leukemia blasts and other noncancerous tissues such as hematopoietic stem cells. On-target off-tumor toxicities may limit chimeric antigen receptor T cell therapies that target both C
Externí odkaz:
https://doaj.org/article/950a3b2659db497d9c16853df8bab008
Autor:
Semira Sheikh, Sepideh Mokhtari, Jeffrey A. Silverman, Kayla Reid, Rawan Faramand, Marco L. Davila, Norman Franke, Frederick L. Locke, Michael D. Jain, Daniel Wong, John G. Kuruvilla
Publikováno v:
eJHaem, Vol 3, Iss 1, Pp 223-227 (2022)
Externí odkaz:
https://doaj.org/article/13b8610a64c74b59a0dc98940dbbade2
Autor:
Jennifer M. Logue, Elisa Zucchetti, Christina A. Bachmeier, Gabriel S. Krivenko, Victoria Larson, Daniel Ninh, Giovanni Grillo, Biwei Cao, Jongphil Kim, Julio C. Chavez, Aliyah Baluch, Farhad Khimani, Aleksandr Lazaryan, Taiga Nishihori, Hien D. Liu, Javier Pinilla-Ibarz, Bijal D. Shah, Rawan Faramand, Anna E. Coghill, Marco L. Davila, Bhagirathbhai R. Dholaria, Michael D. Jain, Frederick L. Locke
Publikováno v:
Haematologica, Vol 106, Iss 4 (2020)
CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) for relapsed or refractory (R/R) large B cell lymphoma (LBCL) may lead to durable remissions, however, prolonged cytopenias and infections may occur. In this single center retrospective s
Externí odkaz:
https://doaj.org/article/9b49d260a7484ec48b00e7dc0cef6f14
Autor:
Kenneth Cornetta, Lisa Duffy, Steven A. Feldman, Crystal L. Mackall, Marco L. Davila, Kevin J. Curran, Richard P. Junghans, Jean Yuh Tang, James N. Kochenderfer, Roisin O’Cearbhaill, Gary Archer, Hans-Peter Kiem, Nirali N. Shah, Cindy Delbrook, Rosie Kaplan, Renier J. Brentjens, Isabelle Rivière, Michel Sadelain, Steven A. Rosenberg
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 10, Iss , Pp 371-378 (2018)
Replication-competent retrovirus (RCR) is a safety concern for individuals treated with retroviral gene therapy. RCR detection assays are used to detect RCR in manufactured vector, transduced cell products infused into research subjects, and in the r
Externí odkaz:
https://doaj.org/article/d41ec9a65e514c438579bc848efe4243
Autor:
Scott Christley, Walter Scarborough, Eddie Salinas, William H. Rounds, Inimary T. Toby, John M. Fonner, Mikhail K. Levin, Min Kim, Stephen A. Mock, Christopher Jordan, Jared Ostmeyer, Adam Buntzman, Florian Rubelt, Marco L. Davila, Nancy L. Monson, Richard H. Scheuermann, Lindsay G. Cowell
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
BackgroundRecent technological advances in immune repertoire sequencing have created tremendous potential for advancing our understanding of adaptive immune response dynamics in various states of health and disease. Immune repertoire sequencing produ
Externí odkaz:
https://doaj.org/article/ccf807b5dbf248eeac1ed7188f9e63bd
Autor:
David A Sallman, Tessa Kerre, Violaine Havelange, Xavier Poiré, Philippe Lewalle, Eunice S Wang, Jason B Brayer, Marco L Davila, Ine Moors, Jean-Pascal Machiels, Ahmad Awada, Erik M Alcantar-Orozco, Rossitza Borissova, Nathalie Braun, Marie-Sophie Dheur, David E Gilham, Caroline Lonez, Frédéric F Lehmann, Anne Flament
Publikováno v:
The Lancet Haematology. 10:e191-e202
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::857210f428efc78f80e65da7390d8fd8
https://doi.org/10.1016/s2352-3026(22)00378-7
https://doi.org/10.1016/s2352-3026(22)00378-7
Autor:
Justin C, Boucher, Bin, Yu, Gongbo, Li, Bishwas, Shrestha, David, Sallman, Ana Marie, Landin, Cheryl, Cox, Kumar, Karyampudi, Claudio, Anasetti, Marco L, Davila, Nelli, Bejanyan
Publikováno v:
Journal of Immunotherapy. 46:5-13
Higher γδ T cell counts in patients with malignancies are associated with better survival. However, γδ T cells are rare in the blood and functionally impaired in patients with malignancies. Promising results are reported on the treatment of vario
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df8dbb968c08337b9fe2b097b83dfb51
https://doi.org/10.1097/cji.0000000000000445
https://doi.org/10.1097/cji.0000000000000445
Autor:
Michael D. Jain, Bachisio Ziccheddu, Caroline A. Coughlin, Rawan Faramand, Anthony J. Griswold, Kayla M. Reid, Meghan Menges, Yonghong Zhang, Ling Cen, Xuefeng Wang, Mohammad Hussaini, Ola Landgren, Marco L. Davila, Jonathan H. Schatz, Frederick L. Locke, Francesco Maura
Publikováno v:
Blood. 140:491-503
CD19-directed chimeric antigen receptor (CAR-19) T cells are groundbreaking immunotherapies approved for use against large B-cell lymphomas. Although host inflammatory and tumor microenvironmental markers associate with efficacy and resistance, the t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa285563b44c42df890af2e335e6e767
https://doi.org/10.1182/blood.2021015008
https://doi.org/10.1182/blood.2021015008